To compare utilization trends of multiple sclerosis (MS) disease-modifying therapies (DMT) between the Department of Veterans Affairs (VA) and US Medicare healthcare programs.
No takes yet. Share an insight, caveat, or question.
Spain et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: